Search

The inaugural Kravis WiSE Symposium will take place virtually July 8-20, 2020. Each talk will be broadcast as part of the MSK Science Spotlight series, which is available via livestream and open to all.

… Tuesday, July 7, 2020 MSK has recently announced the establishment of the Marie-Josée Kravis Women in Science Endeavor ( WISE ) to provide financial and professional support to women scientists pursuing biomedical research at MSK, pledging its commitment to gender equity in science and paving the way

New MSK research discovered ferroptosis regulators that suggest therapeutic opportunities against hormone receptor-positive cancers; examined how tumor-associated macrophages might be turned against cancer; acquired new insights into joint inflammation in rheumatoid arthritis; developed a systems-level platform called epichaperomics to map changes in interactors among thousands of proteins involved in cancer-related processes; and investigated how artificial intelligence could help diagnose an invasive form of breast cancer.

… Thursday, June 29, 2023 New research from  Memorial Sloan Kettering Cancer Center (MSK)  and the  Sloan Kettering Institute  — a hub for basic science and translational research within MSK — discovered ferroptosis regulators that suggest therapeutic opportunities against hormone receptor-positive cancers

MSK has joined with 68 of the nation’s top cancer centers in issuing a statement urging increased HPV vaccination for the prevention of cancer. This statement, signed by MSK Physician-in-Chief and Chief Medical Officer José Baslega, MD, PhD, and colleagues at NCI-designated cancer centers across the country, calls upon the nation’s physicians, parents, and young adults to take advantage of this rare opportunity to prevent many types of cancer. MSK head and neck and gynecologic cancer experts are available to discuss the importance of the HPV vaccine and risks of HPV-related cancers. Please email [email protected] to arrange an interview.

… Wednesday, January 27, 2016 MSK has joined with 68 of the nation’s top cancer centers in issuing a statement urging increased HPV vaccination for the prevention of cancer. This statement, signed by MSK Physician-in-Chief and Chief Medical Officer José Baslega, MD, PhD, and colleagues at NCI-designated

Minimally invasive surgery (MIS) to resect liver segments 7 and 8 is safe for select patients treated by experienced MIS hepatopancreatobiliary surgeons.

… Tuesday, March 2, 2021 Minimally invasive surgery (MIS) to resect liver segments 7 and 8 is safe for select patients treated by experienced MIS hepatopancreatobiliary surgeons, according to our retrospective study published recently in the Journal of Surgical Oncology .  (1) Whether MIS is a safe and

Researchers have discovered that cancer cells may hijack an immune response to spread from a primary tumor to distant organs.

… Wednesday, January 17, 2018 Summary A new finding suggests that a genetic mistake in cancer cells known as chromosomal instability creates an inflammatory state within the cells. The cancer cells take advantage of this condition by hijacking pathways used by immune cells to migrate. This enables these

Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc., a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center.

… Thursday, December 5, 2013 Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute , Inc. (Tri-I TDI), a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center that is designed to

The FDA has approved the first-ever treatment developed for low-grade serous ovarian cancer, a rare type of ovarian cancer.

… Monday, May 12, 2025 The first drug for a rare and difficult-to-treat type of  ovarian cancer has been granted  accelerated approval by the Food and Drug Administration (FDA). The treatment, called avutometinib plus defactinib (Avmapki TM Fakzynja TM Co-pack), was developed to treat low-grade serous

Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program, is a co-recipient of the 2011 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation.

… Friday, July 1, 2011 Summary Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program, is a co-recipient of the 2011 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation. Charles L. Sawyers , Chair of the Human Oncology and Pathogenesis Program , is a co-recipient

First-year students reflect on the impact of the first-year core curriculum on their careers.

… Thursday, April 1, 2010 Our current first-year students arrived on July 27, 2009, and during their first laboratory rotation began laying the foundation for developing a dissertation. After five weeks of bench work, they entered the classroom to tackle the core course, taking breaks from this didactic

Charles Swanton of Cancer Research UK and University College London was one of the recipients of the 2021 Paul Marks Prize for Cancer Research.

… Thursday, March 17, 2022 The Paul Marks Prize for Cancer Research was created by the Boards of Memorial Sloan Kettering Cancer Center to honor the late Paul Marks , who served as President and CEO of MSK for almost 20 years, beginning in 1980. Awarded every other year since 2001, the prize recognizes